Syversen P V, Saeter U, Cunha-Ribeiro L, Orvim U, Sletten K, Husby G, Sakariassen K S
Department of Biochemistry/Biotechnology Centre of Oslo, University of Oslo, Norway.
Thromb Res. 1994 Nov 1;76(3):299-305. doi: 10.1016/0049-3848(94)90201-1.
The effect of the major acute phase protein serum amyloid A (SAA) on collagen induced platelet aggregation was investigated. A truncated version of SAA, SAA25-76 was tested for inhibitory capacity of collagen induced platelet aggregation in platelet-rich plasma (PRP) and whole blood (WB). The tetrapeptide RGDV, a known inhibitor of platelet aggregation, was included as a reference compound. SAA25-76 at a concentration of 390 micrograms/ml inhibited platelet aggregation induced by 1 microgram/ml of collagen in PRP. This corresponds to the plasma concentration of SAA during an acute phase response. However, the inhibitory effect of the SAA25-76 fragment was lost at higher collagen concentrations (> or = 2.0 micrograms/ml). The SAA fragment at 390 micrograms/ml had no significant effect on platelet aggregation in WB. In contrast, RGDV blocked collagen induced platelet aggregation in both PRP and WB.
研究了主要急性期蛋白血清淀粉样蛋白A（SAA）对胶原诱导的血小板聚集的影响。测试了截短形式的SAA，即SAA25 - 76对富含血小板血浆（PRP）和全血（WB）中胶原诱导的血小板聚集的抑制能力。包含已知的血小板聚集抑制剂四肽RGDV作为参考化合物。浓度为390微克/毫升的SAA25 - 76抑制了PRP中1微克/毫升胶原诱导的血小板聚集。这与急性期反应期间SAA的血浆浓度相对应。然而，在较高的胶原浓度（≥2.0微克/毫升）下，SAA25 - 76片段的抑制作用消失。390微克/毫升的SAA片段对WB中的血小板聚集没有显著影响。相比之下，RGDV在PRP和WB中均能阻断胶原诱导的血小板聚集。
